

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/137078 A1

- (51) **International Patent Classification:**
C07K 14/245 (2006.01) *A61K 39/108* (2006.01)
- (21) **International Application Number:**
PCT/IB2021/062022
- (22) **International Filing Date:**
20 December 2021 (20.12.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/130,153 23 December 2020 (23.12.2020) US
63/185,425 07 May 2021 (07.05.2021) US
63/282,244 23 November 2021 (23.11.2021) US
- (71) **Applicant: PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors: CHE, Ye;** c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **CHORRO, Laurent Oliver;** c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **DONALD, Robert George Konrad;** c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US). **GRIFFOR, Matthew Curtis;** 386 Wyassup Road, North Stonington, Connecticut 06359 (US). **SILMON DE MON-**

ERRI, Natalie Clare; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, New York 10965 (US).


(74) **Agent: ZIELINSKI, Bryan C.;** Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** E. COLI FIMH MUTANTS AND USES THEREOF

FIG. 3A



(57) **Abstract:** This disclosure relates to the design of *E.coli* mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*